compound glp 1 ban Compounded GLP-1 ban: What providers need to know Compounded GLP-1 drugs aren't going

BPC-157 is a synthetic peptide investigated in preclinical and animal research for tissue-repair signaling, angiogenesis, and gut-lining studies

The reconstitution process involves incorporating a measure of bacteriostatic water with the powder and gently mixing them together until the powder is dissolved

The article's own clinical relevance column calls that encouraging but insufficient for clinical recommendations

Practices that compound on-site will need additional equipment

considering the brain and the CNS specifically, BBB penetration rates and the P-glycoprotein (P-gp) efflux pump are critical factors limiting their application in the clinic [1]